DTS-108, a novel peptidic prodrug of SN38: In vivo efficacy and toxicokinetic studies

Clinical Cancer Research

Volumn 14, Issue 7, 2008, Pages 2145-2153

  Meyer Losic, Florence ^a   Nicolazzi, Céline ^a   Quinonero, Jérôme ^a   Ribes, Fabien ^a   Michel, Matthieu ^a   Dubois, Vincent ^a   De Coupade, Catherine ^a   Boukaissi, Matthieu ^a   Chéné, Anne Sophie ^a   Tranchant, Isabelle ^a   Arranz, Valérie ^a   Zoubaa, Imane ^a   Fruchart, Jean Sébastien ^a   Ravel, Denis ^a   Kearsey, Jonathan ^a  

^a Diatos SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; DTS 108; FLUOROURACIL; IRINOTECAN; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; CELL VIABILITY; COLON TUMOR; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; LEUKOPENIA; LIVER METABOLISM; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICOKINETICS; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CATIONS; DOGS; DRUG CARRIERS; HUMANS; NEOPLASMS, EXPERIMENTAL; PEPTIDES; PRODRUGS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42249108725     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4580     Document Type: Article

References (44)

1. Hartmann JT, Lipp H-P. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf 2006;29:209-30.
2. Pessino A, Sobrero A. Optimal treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther 2006;6:801-12.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
4. Vanhoefer U, Rougier P, Borner M, Munoz A, Van Laethem J-L, Sobrero A. Irinotecan in combination with new agents. Second Clinical Investigators Update Meeting on Gastrointestinal Cancer. Eur J Cancer Suppl 2004;2:14-20.
5. Mathijssen RHJ, Loos WJ, Verweij J, Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002;2:103-23.
6. Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 2006;20:163-75.
7. Senter PD, Beam KS, Mixan B, Wahl AF. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Bioconjug Chem 2001;12:1074-80.
8. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000;60:1189-92.
9. Charasson V, Haaz M-C, Robert J. Determination of drug interactions occurring with the metabolic pathways of irinotecan. Drug Metab Dispos 2002;30:731-3.
10. de Jong FA, de Jonge MJA, Verweij J, Mathijssen RHJ. Role of pharmacogenetics in irinotecan therapy. Cancer Lett 2006;234:90-106.
11. Treinen-Moslen M, Kanz MF. Intestinal tract injury by drugs: Importance of metabolite delivery by yellow bile road. Pharmacol Ther 2006;112:649-67.
12. Horikawa M, Kato Y, Sugiyama Y. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res 2002;19:1345-53.
13. Alimonti A, Gelibter A, Pavese I, et al. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev 2004;30:555-62.
14. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 2002;72:265-75.
15. Ychou M, Raoul JL, Desseigne F, et al. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol 2002;50:383-91.
16. 2) according to toxicity prognostic factors. Anticancer Drugs 2004;15:835-41.
17. Van Cutsem E, Dirix L, Van Laethem JL, et al. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer 2005;92:1055-62.
18. De Coupade C, Fittipaldi A, Chagnas V, et al. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem J 2005;390:407-18.
19. Kearsey J. Strategies for highly targeted intracellular drug delivery. Drug Deliv 2004;3:17-9.
20. Meyer-Losic F, Quinonero J, Dubois V, et al. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell). J Med Chem 2006;49:6908-16.
21. Jinno H, Tanaka-Kagawa T, Hanioka N, et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 2003;31:108-13.
22. OECD guideline: Guideline for the testing of chemicals. Section1: Physical chemical properties. 105 Water solubility. Adopted 27.07.95.
23. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 1996;23:11-20.
24. nd ed. Br J Cancer 1998;77:1-10.
25. Azrak RG, Cao S, Slocum HK, et al. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 2004;10:1121-9.
26. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of antiepidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003.
27. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000;60:2190-6.
28. Michel M, Ravel D, Ribes F, Tranchant I. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same. PCT WO 2007/113687,2007.
29. Pavillard V, Agostini C, Richard S, Charasson V, Montaudon D, Robert J. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol 2002;49:329-35.
30. Inaba M, Ohnishi Y, Ishii H, et al. Pharmacokinetics of CPT-11 in rhesus monkeys. Cancer Chemother Pharmacol 1998;41:103-8.
31. Li B, Sedlacek M, Manoharan I, et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005;70:1673-84.
32. Morton CL, Wierdl M, Oliver L, et al. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res 2000;60:4206-10.
33. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994;17:662-4.
34. Sparreboom A, de Jonge MJ, de Bruijn P, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998;4:2747-54.
35. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human livermicrosomes. J Clin Invest 1998;101:847-54.
36. Mick R, Gupta E, Vokes EE, Ratain MJ. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 1996;14:2012-9.
37. Hahn KK, Wolff JJ, Kolesar JM. Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm 2006;63:2211-7.
38. Marsh S. Impact of pharmacogenomics on clinical practice in oncology. Mol Diagn Ther 2007;11:79-82.
39. Kawano K, Watanabe M, Yamamoto T, et al. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J Control Release 2006;112:329-32.
40. Schluep T, Hwang J, Cheng J, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 2006;12:1606-14.
41. Sadzuka Y, Takabe H, Sonobe T. Liposomalization of SN-38 as active metabolite of CPT-11. J Control Release 2005;108:453-9.
42. Bhatt R, de Vries P, Tulinsky J, et al. Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 20S-camptothecin. J Med Chem 2003;46:190-3.
43. Tatalick LM, Hughes M, Spurgeon S, et al. Preclinical results with SN2310 emulsion indicates improved pharmacokinetic and pharmacodynamic profiles compared to irinotecan. Proceedings of AACR-NCI-EORTC international conference 2005. Session A (abstracts no A220); 2005.
44. Gandia D, Abigerges D, Armand JP, et al. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 1993;11:196-7